| 6 |  | Defending No - Xavier Carné (Spain) |
| 1 |  | Miriam CJM Sturkenboom (The Netherlands) |
| 2 |  | Pharmacoeconomic evaluation of pharmacogenomics implementation from healthcare systems perspective - Raul A. Kiivet (Estonia) |
| 6 |  | Defending Yes - Ruth Diazaraque (United Kingdom) |
| 2 |  | "Increasingly No" - Tom MacDonald (United Kingdom) |
| 1 |  | Personalised pharmacotherapy in routine clinical pharmacological practice - Milan Grundmann (Czech Republic) |
| 2 |  | Promoting utility of PK/TDM principles among practitioners facilitates dialog towards rationalization of drug use - Romaldas Maciulaitis (Lithuania) |
| 1 |  | www.farmakologiportalen.no. A common national database for pharmacological laboratory services - Tormod K Bjånes (Norway) |
| 1 |  | Presentation of two controversial examples - Antonio Gomez-Outes |
| 2 |  | General considerations about CHMP opinions - Centralized Procedure - Martina Weise |
| 2 |  | Presentation of two controversial examples - Jorge Camarero |
| 4 |  | Introduction and General considerations about CHMP opinions - Arantxa Sancho |
| 3 |  | Understanding the pharmacological factors that influence heterogeneity in drug response - Juan Tamargo (Spain) |
| 3 |  | Hepatitis B reactivation. How to manage the risk? - José Luis Calleja (Spain) |
| 2 |  | Progressive multifocal leukoencephalopathy. Risk perception in the therapeutic context - Brigitte Keller-Stanislawski (Germany) |
| 2 |  | Registries for long-term risks - Ignacio García Doval (Spain) |
| 2 |  | Heterogeneity, the problem with the averages and the new regulatory challenge: “whom to treat” - Caridad Pontes (Spain) |
| 1 |  | Variability in drug response and clinical reality: the example of psychiatric diseases - Eduard Vieta (Spain) |
| 2 |  | Systematic introduction of new therapies within the Stockholm county and the Karolinska University Hospital - Carl-Olav Stiller (Sweden) |
| 2 |  | A computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents. The PRESCRIB Project - Cándido Hernández-López (Spain) |
| 2 |  | Rational pharmacotherapy in children - issues concerning off-label drug use - Imti Choonara (United Kingdom) |
| 2 |  | Public support to independent clinical trials - Rafael de Andrés Medina (Spain) |
| 4 |  | Renal function in older people - validity of MDRD/CG/CKD-EPI and implication for clinical practice - Emmanuelle Vidal-Petiot (France) |
| 2 |  | Shifting the marketing authorisation paradigm? Adaptive licensing: A valid approach nowadays? - Bruno Flamion (Belgium) |
| 1 |  | What is lacking in the regulatory package to support reimbursement decisions? - Beate Wieseler (Germany) |
| 1 |  | Update in strategies for appropriate prescription in older patients - Beatriz Montero (Spain) |
| 1 |  | Physiologically-based pharmacokinetic models to predict ADME in humans - Amin Rostami (United Kingdom) |
| 2 |  | Drug interactions at the level of influx transporters - Janne Backman (Finland) |
| 1 |  | Challenges in communicating risks -Barbara Rath (Germany) |
| 1 |  | Biomarkers in Alzheimer clinical research - Claudio Babiloni (Italy) |
| 11 |  | Challenging issues of the introduction of biosimilar in clinical practice: Interchangeability, substitution, and traceability. Cristina Avendaño-Solá (Spain) |
| 16 |  | Biosimilar regulation in the EU. Trends for the future (e.g. extrapolation of indications, how to conciliate therapeutic equivalence demonstration with assay sensitivity) - Martina Weise (Germany) |
| 6 |  | Impact of biosimilar medicinal products in the EU pharmaceutical market - Aleksandra Grozdanova (Macedonia) |
| 1 |  | Current challenges in cancer treatment. Luis Paz Ares (Spain) |
| 1 |  | Targeting TNF receptors in neurodegenerative diseases - Roman Fischer (Germany) |
| 2 |  | The Sfinx/Pharao CDSS on drug-drug interactions and pharmacodynamics. Ylva Böttiger (Sweden) |
| 1 |  | Re-engineering the WHO Essential Medicines process: Moving towards a globally applicable model. Nicola Magrini (WHO, Switzerland) |
| 1 |  | The intestinal microbiota in the pathogenesis of metabolic syndrome |
| 1 |  | EACPT focus meeting July 2014 |
| 1 |  | EACPT Riksen Trained Immunity |
| 1 |  | 1 st- 2014 EACP Nijmegen talk final |
